Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alloreactive cytotoxic T lymphocytes + interleukin-2
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
Alloreactive cytotoxic T lymphocytes (alloCTL) combined with interleukin-2 (IL-2) is an experimental cellular immunotherapy developed by the Jonsson Comprehensive Cancer Center (UCLA) for the treatment of recurrent malignant gliomas and malignant meningiomas. This biologic therapy consists of ex vivo activated alloreactive cytotoxic T lymphocytes that are sensitized to the patient's major histocompatibility complex (MHC) proteins. The therapy involves generating alloCTL from MHC-disparate donor lymphocytes through mixed lymphocyte reactions over a 2-3 week period. These sensitized cells are then administered intratumorally or into the tumor cavity along with IL-2, which serves as a growth factor to support the survival and anti-tumor activity of the T cells. The mechanism of action relies on the selective recognition and killing of glioma cells expressing the targeted MHC proteins by the donor-derived cytotoxic T cells.
- Other names
- alloreactive CTLaCTLcellular immunotherapy with alloCTL and IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on alloreactive cytotoxic T lymphocytes + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alloreactive cytotoxic T lymphocytes + interleukin-2.